U.S. patent application number 14/845065 was filed with the patent office on 2015-12-31 for method for controlling streptococcus pneum0niae polysaccharide molecular weight using carbon dioxide.
The applicant listed for this patent is Wyeth LLC. Invention is credited to Jean Heather Crinean.
Application Number | 20150376667 14/845065 |
Document ID | / |
Family ID | 41666441 |
Filed Date | 2015-12-31 |
United States Patent
Application |
20150376667 |
Kind Code |
A1 |
Crinean; Jean Heather |
December 31, 2015 |
METHOD FOR CONTROLLING STREPTOCOCCUS PNEUM0NIAE POLYSACCHARIDE
MOLECULAR WEIGHT USING CARBON DIOXIDE
Abstract
The present invention provides improved methods for producing a
solution containing high molecular weight isolated Streptococcus
pneumoniae capsular polysaccharides having phosphodiester linkages
between saccharide repeat units. In certain methods, CO.sub.2 is
supplied to a fermentation culture of Streptococcus pneumoniae
bacterial cells that produce capsular polysaccharide serotypes
containing phosphodiester linkages between saccharide repeat units.
Exemplary Streptococcus pneumoniae serotypes containing a
phosphodiester linkage between saccharide repeat units include
serotypes 6A, 6B, 19A, and 19F. Supplying CO.sub.2 to the
fermentation culture includes adding bicarbonate ions to the
fermentation culture, adding carbonate ions to the fermentation
culture, adding mixtures of bicarbonate and carbonate ions to the
fermentation culture, and overlaying the fermentation culture with
CO.sub.2.
Inventors: |
Crinean; Jean Heather;
(Saint Charles, MO) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Wyeth LLC |
New York |
NY |
US |
|
|
Family ID: |
41666441 |
Appl. No.: |
14/845065 |
Filed: |
September 3, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12640666 |
Dec 17, 2009 |
|
|
|
14845065 |
|
|
|
|
61138570 |
Dec 18, 2008 |
|
|
|
Current U.S.
Class: |
435/101 |
Current CPC
Class: |
C08L 2203/02 20130101;
C12N 1/20 20130101; C12P 19/04 20130101; A61K 39/092 20130101; C08L
5/00 20130101 |
International
Class: |
C12P 19/04 20060101
C12P019/04 |
Claims
1. A method for producing a solution containing high molecular
weight isolated Streptococcus pneumoniae capsular polysaccharides
wherein said polysaccharides comprise phosphodiester linkages
between repeat units, the method comprising: a) preparing a
fermentation culture of Streptococcus pneumoniae bacterial cells
that produce capsular polysaccharides comprising a phosphodiester
linkage between repeat units; b) overlaying the fermentation
culture with CO.sub.2; c) lysing the bacterial cells in said
fermentation culture; and d) isolating Streptococcus pneumoniae
capsular polysaccharides from said fermentation culture; whereby a
solution is produced that contains high molecular weight isolated
Streptococcus pneumoniae capsular polysaccharides wherein said
polysaccharides comprise phosphodiester linkages between repeat
units.
2. The method of claim 1, wherein said Streptococcus pneumoniae
capsular polysaccharides are serotype 19A.
3. The method of claim 1, wherein said Streptococcus pneumoniae
capsular polysaccharides are serotype 6A.
4. The method of claim 1, wherein said Streptococcus pneumoniae
capsular polysaccharides are serotype 19F.
5. The method of claim 1, wherein said Streptococcus pneumoniae
capsular polysaccharides are serotype 6B.
6. The method of claim 1, wherein the pH of said fermentation
culture is between 6 and 7.
7. The method of claim 1, wherein NaOH is added to the fermentation
culture as a base titrant.
8. The method of claim 1, wherein lysing the Streptococcus
pneumoniae in said resultant fermentation culture of step c)
further comprises adding sodium deoxycholate to said fermentation
culture.
9. The method of claim 1, wherein the molecular weight of said
isolated Streptococcus pneumoniae capsular polysaccharide is at
least 480 kDa.
10. The method of claim 9, wherein said molecular weight is at
least 550 kDa.
11. The method of claim 10, wherein said molecular weight is at
least 600 kDa.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 12/640,666, filed Dec. 17, 2009, which claims the benefit of
U.S. Provisional Application No. 61/138,570, which was filed on 18
Dec. 2008, all of which are incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The invention relates to methods for increasing the
molecular weight of isolated Streptococcus pneumoniae capsular
polysaccharides having a phosphodiester linkage between saccharide
repeat units.
BACKGROUND
[0003] In the preparation of multivalent conjugate pneumococcal
vaccines directed to the prevention of invasive diseases caused by
the organism Streptococcus pneumoniae (also known as pneumococcus),
selected Streptococcus pneumoniae serotypes are grown to supply
polysaccharides needed to produce the vaccine. The cells are grown
in fermentors with lysis induced at the end of the fermentation by
addition of sodium deoxycholate or an alternate lysing agent. The
lysate broth is then harvested for downstream purification and the
recovery of the capsular polysaccharide which surrounds the
bacterial cells. After conjugation with a carrier protein, the
polysaccharide is included in the final vaccine product and confers
immunity in the vaccine's target population to the selected
Streptococcus pneumoniae serotypes.
[0004] Polysaccharide size is a quality attribute assayed for in
each preparation batch and must be appropriately controlled.
Traditional processing has involved using NaOH (sodium hydroxide)
as a base titrant during fermentation. The use of NaOH has the
advantage of being able to lower the pH of the deoxycholate lysate
without foaming to remove protein and improve filtration. This
material is subjected to centrifugation followed by filtration to
remove most of the solids down to a 0.45 .mu.m nominal size.
However, such traditional processing methods result in lower
molecular weight polysaccharide (<450 kDa) for serotypes having
a phosphodiester linkage between saccharide repeat units (e.g., 6A,
6B, 19A, and 19F).
[0005] Accordingly, improved methods for the recovery of high
molecular weight capsular polysaccharide from cellular
Streptococcus pneumoniae lysates, in particular lysates containing
Streptococcus pneumoniae serotype 6A, 6B, 19A, or 19F
polysaccharides, are needed.
BRIEF SUMMARY OF THE INVENTION
[0006] Improved methods for the recovery of high molecular weight
capsular polysaccharides from cellular Streptococcus pneumoniae
lysates containing serotypes having a phosphodiester linkage
between saccharide repeat units are provided. In one method,
CO.sub.2 is supplied to a fermentation culture of a Streptococcus
pneumoniae serotype containing a phosphodiester linkage between
saccharide repeat units. Accordingly, in one embodiment of the
invention, the method includes the steps of: 1) preparing a
fermentation culture of Streptococcus pneumoniae bacterial cells
that produce capsular polysaccharides comprising a phosphodiester
linkage between repeat units; 2) supplying CO.sub.2 to the
fermentation culture; 3) lysing the bacterial cells in the
fermentation culture; and 4) isolating Streptococcus pneumoniae
capsular polysaccharides from the fermentation culture, where a
solution containing high molecular weight isolated Streptococcus
pneumoniae capsular polysaccharides containing phosphodiester
linkages between repeat units is produced.
[0007] In a particular embodiment, fermentation cultures of
Streptococcus pneumoniae bacterial cells that produce
polysaccharide serotypes 19A, 6A, 19F, 6B, and combinations thereof
are prepared. In another particular embodiment, supplying CO.sub.2
to the fermentation culture includes adding bicarbonate ion
(HCO.sub.3.sup.-) to the fermentation culture, for example, adding
NaHCO.sub.3 (sodium bicarbonate) to the fermentation culture. In a
further embodiment, supplying CO.sub.2 to the fermentation culture
includes adding carbonate ion (CO.sub.3.sup.2-) to the fermentation
culture, for example, adding Na.sub.2CO.sub.3 (sodium carbonate) to
the fermentation culture. In another embodiment, supplying CO.sub.2
to the fermentation culture includes a first addition of
NaHCO.sub.3 and a second addition of Na.sub.2CO.sub.3. In yet
another embodiment, supplying CO.sub.2 to the fermentation culture
includes overlaying the fermentation culture with CO.sub.2. In
another embodiment, the molecular weight of the isolated
Streptococcus pneumoniae capsular polysaccharide is at least 700
kDa. In another embodiment, a solution containing high molecular
weight isolated Streptococcus pneumoniae capsular polysaccharides
in which the polysaccharides comprise phosphodiester linkages
between repeat units is provided, where the solution is produced by
the method described above. In another embodiment of the present
invention, a method is provided for producing a solution containing
high molecular weight isolated Streptococcus pneumoniae serotype
19A capsular polysaccharides. The method includes the steps of: 1)
preparing a fermentation culture of Streptococcus pneumoniae
bacterial cells that produce serotype 19A capsular polysaccharides;
2) supplying CO.sub.2 to the fermentation culture; 3) lysing the
bacterial cells in the fermentation culture; and 4) isolating
Streptococcus pneumoniae serotype 19A capsular polysaccharides from
the fermentation culture; whereby a solution containing high
molecular weight isolated Streptococcus pneumoniae serotype 19A
capsular polysaccharides is produced. In another embodiment, a
solution containing high molecular weight isolated Streptococcus
pneumoniae serotype 19A capsular polysaccharides is provided, where
the solution is produced by the method described above.
[0008] In another embodiment of the present invention, a method is
provided for producing a solution containing high molecular weight
isolated Streptococcus pneumoniae serotype 19F capsular
polysaccharides. The method includes the steps of: 1) preparing a
fermentation culture of Streptococcus pneumoniae bacterial cells
that produce serotype 19F capsular polysaccharides; 2) supplying
CO.sub.2 to the fermentation culture; 3) lysing the bacterial cells
in the fermentation culture; and 4) isolating Streptococcus
pneumoniae serotype 19F capsular polysaccharides from the
fermentation culture; whereby a solution containing high molecular
weight isolated Streptococcus pneumoniae serotype 19F capsular
polysaccharides is produced. In another embodiment, a solution
containing high molecular weight isolated Streptococcus pneumoniae
serotype 19F capsular polysaccharides is provided, where the
solution is produced by the method described above.
[0009] In another embodiment of the present invention, a method is
provided for producing a solution containing high molecular weight
isolated Streptococcus pneumoniae serotype 6A capsular
polysaccharides. The method includes the steps of: 1) preparing a
fermentation culture of Streptococcus pneumoniae bacterial cells
that produce serotype 6A capsular polysaccharides; 2) supplying
CO.sub.2 to the fermentation culture; 3) lysing the bacterial cells
in the fermentation culture; and 4) isolating Streptococcus
pneumoniae serotype 6A capsular polysaccharides from the
fermentation culture; whereby a solution containing high molecular
weight isolated Streptococcus pneumoniae serotype 6A capsular
polysaccharides is produced. In another embodiment, a solution
containing high molecular weight isolated Streptococcus pneumoniae
serotype 6A capsular polysaccharides is provided, where the
solution is produced by the method described above.
[0010] In another embodiment of the present invention, a method is
provided for producing a solution containing high molecular weight
isolated Streptococcus pneumoniae serotype 6B capsular
polysaccharides. The method includes the steps of: 1) preparing a
fermentation culture of Streptococcus pneumoniae bacterial cells
that produce serotype 6B capsular polysaccharides; 2) supplying
CO.sub.2 to the fermentation culture; 3) lysing the bacterial cells
in the fermentation culture; and 4) isolating Streptococcus
pneumoniae serotype 6B capsular polysaccharides from the
fermentation culture; whereby a solution containing high molecular
weight isolated Streptococcus pneumoniae serotype 6B capsular
polysaccharides is produced. In another embodiment, a solution
containing high molecular weight isolated Streptococcus pneumoniae
serotype 6B capsular polysaccharides is provided, where the
solution is produced by the method described above.
BRIEF DESCRIPTION OF THE DRAWINGS
[0011] FIG. 1 shows the optical density (OD), base and glucose
levels during the fermentation phase with Na.sub.2CO.sub.3 as
titration base from laboratory studies at 3 L scale. Base in grams
is divided by 10 for plotting purposes.
[0012] FIG. 2 shows the optical density (OD), base and glucose
levels during the fermentation phase with NaOH as titration base
from laboratory studies at 3 L scale. Base in grams is divided by
10 for plotting purposes.
[0013] FIG. 3 shows total protein and polysaccharide results at
different pH adjustments for alternate base feeds of
Na.sub.2CO.sub.3 or NaOH.
DETAILED DESCRIPTION OF THE INVENTION
[0014] Streptococcus pneumoniae are Gram-positive, lancet shaped
cocci that are usually seen in pairs (diplococci), but also in
short chains or as single cells. They grow readily on blood agar
plates with glistening colonies and display alpha hemolysis unless
grown anaerobically where they show beta hemolysis. The cells of
most pneumococcal serotypes have a capsule which is a
polysaccharide coating surrounding each cell. This capsule is a
determinant of virulence in humans, as it interferes with
phagocytosis by preventing antibodies from attaching to the
bacterial cells. Currently there are more than 90 known
pneumococcal capsular serotypes identified, with the 23 most common
serotypes accounting for approximately 90% of invasive disease
worldwide.
[0015] As a vaccine, the pneumococcal polysaccharide coat can
confer a reasonable degree of immunity to Streptococcus pneumoniae
in individuals with developed or unimpaired immune systems, but a
conjugated protein with polysaccharide allows for an immune
response in infants and elderly who are also most at risk for
pneumococcal infections. The pneumococcal cells are grown in
fermentors with lysis induced at the end of the fermentation. The
lysate broth is then harvested for downstream purification and the
recovery of the capsular polysaccharides.
[0016] Polysaccharide size is a quality attribute assayed for in
each preparation batch and must be appropriately controlled. The
molecular weight for serotypes having a phosphodiester linkage
between saccharide repeat units (e.g., 6A, 6B, 19A, and 19F) is
affected by parameters of the fermentation process. The methods of
the present invention allow for the recovery of high molecular
weight capsular polysaccharides from cellular Streptococcus
pneumoniae lysates containing serotypes having a phosphodiester
linkage between saccharide repeat units, such as serotype 6A,
serotype 6B, serotype 19A, serotype 19F, and combinations
thereof.
[0017] In the development of the present methods, the concentration
of HySoy and choice of base titrant were modified in an attempt to
modify final polysaccharide yields and molecular weights. Four
fermentation schemes were tested. The first used a baseline NaOH
process with 28 g/L HySoy. The second used 20% sodium carbonate as
the base titrant and 20 g/L HySoy. The third combined advantages of
the first two approaches by introducing carbonate through the
batching of sodium bicarbonate and using a mixed NaOH/carbonate
base titrant. The fourth approach used carbonate as the base
titrant with a 10 mM bicarbonate addition to bolster growth.
[0018] Using NaOH as the base titrant during fermentation had the
advantage of being able to lower the deoxycholate lysate to pH 5.0
without foaming to remove protein and improve filtration, but
resulted in lower molecular weight polysaccharide (<450 kDa).
Na.sub.2CO.sub.3 provided higher molecular weight but had foaming
issues if the pH of the deoxycholate lysate was lowered. At a
higher pH hold step of 6.6, the fermentations using
Na.sub.2CO.sub.3 formed a gel-like material, with subsequent
filtration problems. Minimizing the amount of Na.sub.2CO.sub.3 by
using a blend of NaOH and Na.sub.2CO.sub.3 as a pH titrant provided
the molecular weight size benefits of Na.sub.2CO.sub.3 while
eliminating foaming and filtration problems due to the sudden
release of large amounts of CO.sub.2. The use of 20%
Na.sub.2CO.sub.3 (w/v) as the base titrant with a 10 mM NaHCO.sub.3
addition to bolster growth (fourth approach) produced consistent,
high molecular weight polysaccharides at high yield.
[0019] The present invention thus provides improved methods for the
recovery of high molecular weight capsular polysaccharides from
cellular Streptococcus pneumoniae lysates containing serotypes
having a phosphodiester linkage between saccharide repeat units. In
one method, CO.sub.2 is supplied to a fermentation culture of a
Streptococcus pneumoniae serotype containing a phosphodiester
linkage between saccharide repeat units. Exemplary Streptococcus
pneumoniae serotypes containing a phosphodiester linkage between
saccharide repeat units include serotypes 6A, 6B, 19A, and 19F.
Accordingly, in one embodiment of the invention, a method for
producing a solution containing high molecular weight isolated
Streptococcus pneumoniae capsular polysaccharides that comprise
phosphodiester linkages between repeat units is provided, which
includes the steps of: 1) preparing a fermentation culture of
Streptococcus pneumoniae bacterial cells that produce capsular
polysaccharides comprising a phosphodiester linkage between repeat
units; 2) supplying CO.sub.2 to the fermentation culture; 3) lysing
the bacterial cells in the fermentation culture; and 4) isolating
Streptococcus pneumoniae capsular polysaccharides from the
fermentation culture;
whereby a solution containing high molecular weight isolated
Streptococcus pneumoniae capsular polysaccharides with
phosphodiester linkages between repeat units is produced. In
another embodiment, the present invention relates to a solution
containing high molecular weight isolated Streptococcus pneumoniae
capsular polysaccharides with phosphodiester linkages between
repeat units, where the solution is produced by the method
described above.
[0020] The methods of the invention produce high molecular weight
Streptococcus pneumoniae capsular polysaccharides that comprise
phosphodiester linkages between repeat units (for example,
serotypes 6A, 6B, 19A, and 19F). As used herein, "high molecular
weight" refers to molecular weights that are at least about 480
kDa, about 490 kDa, about 500 kDa, about 510 kDa, about 520 kDa,
about 525 kDa, about 550 kDa, about 575 kDa, about 600 kDa, about
625 kDa, about 650 kDa, about 675 kDa, about 700 kDa, about 725
kDa, about 750 kDa, about 775 kDa, about 800 kDa, about 825 kDa,
about 850 kDa, about 875 kDa, about 900 kDa, about 925 kDa, about
950 kDa, about 975 kDa, or about 1000 kDa.
[0021] In certain methods, supplying CO.sub.2 to the fermentation
culture includes adding bicarbonate ion (HCO.sub.3.sup.-) to the
fermentation culture, for example, adding NaHCO.sub.3 to the
fermentation culture. NaHCO.sub.3 additions of 5-50 mM can be used,
such as 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45
mM, or 50 mM. In other methods, supplying CO.sub.2 to the
fermentation culture includes adding carbonate ion
(CO.sub.3.sup.2-) to the fermentation culture, for example, adding
Na.sub.2CO.sub.3 to the fermentation culture. Na.sub.2CO.sub.3
additions of 0.1 M-2.0 M can be used, such as 0.1 M, 0.2 M, 0.4 M,
0.6 M, 0.7 M, 0.9 M, 1.0 M, 1.5 M, 1.8 M, or 2.0 M. A weight/volume
(w/v) equivalent can also be used, such as 5% (w/v)
Na.sub.2CO.sub.3, 10% (w/v) Na.sub.2CO.sub.3 or 20% (w/v)
Na.sub.2CO.sub.3. In yet other methods, supplying CO.sub.2 to the
fermentation culture includes a first addition of NaHCO.sub.3 and a
second addition of Na.sub.2CO.sub.3 to the fermentation culture. In
further methods, supplying CO.sub.2 to the fermentation culture
includes overlaying the fermentation culture with CO.sub.2.
CO.sub.2 overlays of 5%-100% can be used, for example, 5%, 10%,
15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%,
80%, 85%, 90%, 95%, or 100%.
[0022] Within the methods of the present invention, the bacterial
cells may be lysed using any lytic agent. A "lytic agent" is any
agent that aids in cell wall breakdown and release of autolysin
which causes cellular lysis including, for example, detergents. As
used herein, the term "detergent" refers to any anionic or cationic
detergent capable of inducing lysis of bacterial cells.
Representative examples of such detergents for use within the
methods of the present invention include deoxycholate sodium (DOC),
N-lauryl sarcosine (NLS), chenodeoxycholic acid sodium, and
saponins.
[0023] In one embodiment of the present invention, the lytic agent
used for lysing bacterial cells is DOC. DOC is the sodium salt of
the bile acid deoxycholic acid, which is commonly derived from
biological sources such as cows or oxen. DOC activates the LytA
protein, which is an autolysin that is involved in cell wall growth
and division in Streptococcus pneumoniae. The LytA protein has
choline binding domains in its C-terminal portion, and mutations of
the lytA gene are known to produce LytA mutants that are resistant
to lysis with DOC.
[0024] Although there is no evidence that the use of DOC during
Streptococcus pneumoniae polysaccharide purification poses a health
risk, the use of such biologically derived reagents could raise
potential regulatory concerns. Accordingly, in one embodiment of
the present invention, the lytic agent used for lysing bacterial
cells is a non-animal derived lytic agent. Non-animal derived lytic
agents for use within the methods of the present invention include
agents from non-animal sources with modes of action similar to that
of DOC (i.e., that affect LytA function and result in lysis of
Streptococcus pneumoniae cells). Such non-animal derived lytic
agents include, but are not limited to, analogs of DOC,
surfactants, detergents, and structural analogs of choline, and may
be determined using procedures as described in the Experimental
section herein below. In one embodiment, the non-animal derived
lytic agent is selected from the group consisting of decanesulfonic
acid, tert-octylphenoxy poly(oxyethylene)ethanols (e.g. Igepal.RTM.
CA-630, CAS #: 9002-93-1, available from Sigma Aldrich, St. Louis,
Mo.), octylphenol ethylene oxide condensates (e.g. Triton.RTM.
X-100, available from Sigma Aldrich, St. Louis, Mo.), N-lauryl
sarcosine sodium (NLS), lauryl iminodipropionate, sodium dodecyl
sulfate, chenodeoxycholate, hyodeoxycholate, glycodeoxycholate,
taurodeoxycholate, taurochenodeoxycholate, and cholate. In another
embodiment, the non-animal derived lytic agent is NLS.
[0025] Within the methods of the present invention, Streptococcus
pneumoniae capsular polysaccharides are isolated using standard
techniques known to those skilled in the art. For example,
following fermentation of bacterial cells that produce
Streptococcus pneumoniae capsular polysaccharides, the bacterial
cells are lysed to produce a cell lysate. The capsular
polysaccharides may then be isolated from the cell lysate using
purification techniques known in the art, including the use of
centrifugation, precipitation, ultra-filtration, and column
chromatography (See, for example, U.S. Patent App. Pub. Nos.
20060228380, 20060228381, 20070184071, 20070184072, 20070231340,
and 20080102498).
[0026] The process changes described above allow for the recovery
of high molecular weight capsular polysaccharides from cellular
Streptococcus pneumoniae lysates containing serotypes having a
phosphodiester linkage between saccharide repeat units, such as
serotype 6A, serotype 6B, serotype 19A, serotype 19F, and
combinations thereof. This is a robust improvement of the
fermentation/recovery process that can greatly enhance the
production of pneumococcal polysaccharides.
[0027] The following examples are offered by way of illustration
and not by way of limitation.
EXAMPLES
[0028] Selected Streptococcus pneumoniae serotypes were grown to
supply polysaccharides needed to produce vaccines for active
immunization against invasive disease caused by Streptococcus
pneumoniae due to capsular serotypes included in the vaccine. The
cells were grown in fermentors with lysis induced at the end of the
fermentation. The lysate broth was then harvested for downstream
purification and the recovery of the capsular polysaccharides.
Because polysaccharide size is a quality attribute assayed for in
each preparation batch, polysaccharide size must be appropriately
controlled. The molecular weight for serotypes having a
phosphodiester linkage between saccharide repeat units (e.g., 6A,
6B, 19A, and 19F) was found to be affected by parameters of the
fermentation process. The following example describes studies
relating to the supply of CO.sub.2 during fermentation of
Streptococcus pneumoniae serotypes having a phosphodiester linkage
between repeat units to improve polysaccharide molecular
weight.
Example 1
Carbon Dioxide Supply Effect on Polysaccharide Molecular Weight
Fermentation
[0029] Laboratory runs were performed in 3 L Braun Biostat B
fermentors (B. Braun Biotech, Allentown, Pa.). They were filled
with 1.8 L of HYS medium (20 g/L HySoy, 2.5 g/L NaCl, 0.5 g/L
KH.sub.2PO.sub.4, 0.013 g/L CaCl.sub.2.2H.sub.2O, 0.15 g/L
L-Cysteine HCl). The fermentors were then autoclaved for 60 minutes
at 121.degree. C. After cooling, either 40 or 60 mL/L of a 50%
Glucose+1% Magnesium Sulfate (w/v) (DMS) solution was added to each
unit. If required, sodium bicarbonate was added prior to
inoculation.
[0030] Two 2 L seed bottles containing 1 L of HYS media were
inoculated with Type 19A or Type 6A frozen seed stocks and
incubated at 36.degree. C. without shaking for approximately 6-8
hours. Inoculation of the fermentors was performed with a volume of
100 mL (.about.5.2% v/v) aliquoted from a bottle with an OD.sub.600
between 0.3-0.9 and pH between 4.75-5.60. The fermentation
temperature and pH were controlled at the desired setpoints. The
standard conditions of 36.degree. C., 1 L/min air overlay, pH
controlled to 7 and agitation of 75 rpm were used. Two impellers
were placed at the low and middle positions on the agitator shaft.
A bottle containing the appropriate base titrant (3 N NaOH, 3 N
NaOH blended with various concentrations of NaHCO.sub.3, 3 N NaOH
blended with various concentrations of Na.sub.2CO.sub.3 and
NaHCO.sub.3, and 20% Na.sub.2CO.sub.3) was hooked up for automatic
pH control. The fermentors were sampled at various time points for
external pH, OD.sub.600, glucose, polysaccharide, and protein. The
runs were terminated when the glucose concentration was near
depletion, or no increase in OD over time was noted.
Optical Density (OD.sub.600) Measurement
[0031] The cellular density of the fermentation broth was
determined by reading the absorbance of the samples at 600 nm using
a Shimadzu (Columbia, Md.) UV-1601 (2 nm bandwidth) or Spectronics
(Westbury, N.Y.) Genesys 5 spectrophotometer (5 nm bandwidth). The
unit was blanked with the HYS medium diluted with de-ionized (DI)
water to match the dilution required of the sample. The sample was
diluted to keep the absorbance below a reading of 0.4, which is
well within the linear range of the spectrophotometer.
Glucose Concentration
[0032] Glucose levels were determined by centrifuging out the cells
and using the supernatant straight or 3.times. diluted with DI
water. The samples were analyzed on a Nova Biomedical (Waltham,
Mass.) BioProfile 400.
Polysaccharide Analysis
[0033] Samples were taken at the final fermentation reading and
treated with 12% sodium deoxycholate (DOC) to a concentration of
0.13% (w/v) and gently agitated. They were held between 8-24 hours
at 5.degree. C. then pH adjusted to 5.0 with 50% acetic acid to
precipitate out most of the DOC and protein. After another hold
interval of 12-24 hours at 5.degree. C., the samples were
centrifuged (14000 rpm, Sorvall (Thermo Fisher Scientific, Waltham,
Mass.) SS34 rotor, 10 min at 15.degree. C.). The pH of the
supernatant was adjusted to 6.0. The supernatant was then filtered
through 0.45 .mu.m Pall (East Hills, N.Y.) HT Tuffryn Membrane
syringe filters (low protein binding). The filtered product was
analyzed by high-performance size exclusion chromatography
(HPLC-SEC) using standard methodology well known in the art (see,
e.g., Aguilar, M. "HPLC of Peptides and Proteins: Methods and
Protocols" Totowa, N.J.: Humana Press (2004)).
Protein Analysis
[0034] Protein levels were analyzed by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) methods well known in
the art (see, e.g., Walker, J. M. "The Protein Protocols Handbook"
Totowa, N.J.: Humana Press (2002)). The filtered cell lysate
(supernatant) as prepared above was aliquoted into microfuge tubes
at 65 .mu.L/tube. Additions of reducing agent (10 .mu.L
dithiothreitol (DTT)) and NuPAGE.RTM. (Invitrogen, Carlsbad,
Calif.) 4.times. lithium dodecyl sulfate (LDS) sample buffer (25
.mu.L) were made to each sample. The samples were vortexed and
heated for 10 minutes prior to 10 .mu.L/lane loading on NuPAGE.RTM.
4-12% Bis-Tris 12 well gels. The gels were run in NuPAGE.RTM.
MES-SDS buffer at 150 V limiting for approximately 60 minutes and
subsequently stained using the Zoion staining protocol (Zoion
Biotech, Worcester, Mass.). Sample analysis was performed using an
UVP Imager (UVP Inc., Upland, Calif.) with LabWorks.TM. (UVP Inc.)
V.3 software to obtain approximate concentrations of specific
protein bands of interest. Bovine Serum Albumin (BSA) Fraction V
was used to develop a protein standard curve to calculate the
approximate protein values of the samples (in lysed cell
broth).
Molecular Weight Analysis
[0035] Fermentation samples of 1-2 liters were treated with 12%
sodium DOC to a concentration of 0.13% (w/v) with agitation at 200
rpm. Samples were held between 8-24 hours at either 5.degree. C. or
20.degree. C. The samples were then pH adjusted to 5.0 or 6.6 with
50% acetic acid to precipitate out most of the DOC and protein.
After another hold interval of 12-24 hours at 5.degree. C., the
samples were centrifuged (11000 rpm, Sorvall (Thermo Fisher
Scientific, Waltham, Mass.) SLA-3000 rotor, 15 min at 10.degree.
C.). The supernatant samples were then pH adjusted to 6.0 with 3 N
NaOH, and filtered using 0.45 .mu.m Millipore (Billerica, MA) MP60
filters. The samples were then subjected to a modified purification
process consisting of 100K molecular weight cut-off (MWCO)
diafiltration (5.times. concentration followed by 7.5.times.
diafiltration with DI water), 0.1% HB precipitation, and carbon
filtration. The purified material was then subjected to Multi Angle
Laser Light Scattering (MALLS) analysis.
Fermentation Process Study
[0036] Based on previous studies, the fermentation process was
optimized by switching from Na.sub.2CO.sub.3 to NaOH as the base
titrant. Use of NaOH allowed the recovery pH to be lowered to 5.0
resulting in significant protein precipitation. Na.sub.2CO.sub.3
will release CO.sub.2 at low pH (<6.6) creating foam formation.
The impact of base titrant on Type 19A polysaccharide and protein
levels was examined. Two 3 L fermentors were set up with one
fermentor serving as the original process control, using 20%
Na.sub.2CO.sub.3 solution (w/v) as the base feed. The other
fermentor used 3 N NaOH as the base feed.
[0037] During the recovery phase, cells were lysed in the fermentor
with DOC (final concentration 0.13% (w/v)) with the fermentor held
at 36.degree. C. for 30 minutes. Following this step, the lysate
was held overnight with agitation at ambient temperature
(22.degree. C.). After the lysate hold, the lysate was pH titrated
through a range from unadjusted to 4.5 with samples pulled at
various pH setpoints. These samples were held overnight at ambient
temperature prior to being processed and analyzed for
polysaccharide and protein concentrations. The OD, base and glucose
levels during the fermentation phase are shown in FIG. 1 and FIG.
2. The major difference was a higher final OD for the carbonate
run.
[0038] The effect of post DOC lysate pH adjustment on total protein
levels was also examined, and is shown in FIG. 3. The lower pH
levels reduced the protein load in cell free broth for both the
NaOH run and the Na.sub.2CO.sub.3 run. The lower pH (<6.6) had
no negative impact on the polysaccharide yield. The fermentation
analysis results served as an indication that the NaOH base feed
was an acceptable alternative to the process using the
Na.sub.2CO.sub.3 base feed during fermentation, but produced lower
yields than what was obtained with the Na.sub.2CO.sub.3 feed.
Effect of Base Titrant on 19A and 6A Molecular Weight
[0039] A set of fermentations at the 3 L scale were performed to
determine if the base titrant, HySoy concentration and pH hold step
affected serotype 19A molecular weight. The molecular weight
determination was performed using MALLS assay following the
modified purification process. Results are shown in Table 1. For
serotype 6A, only the base titrant was evaluated. Results are shown
in Table 2.
TABLE-US-00001 TABLE 1 Impact of base titrant on 19A molecular
weight (L29331-94) MALLS Run No. pH/Temp HySoy pH Hold Base (kDa) D
7.0/36.degree. C. 28 g/L 5.0 3N NaOH 340 E 7.0/36.degree. C. 20 g/L
5.0 3N NaOH 350 F 7.0/36.degree. C. 20 g/L 5.0 20% Na.sub.2CO.sub.3
713 H 7.0/36.degree. C. 20 g/L 6.6 20% Na.sub.2CO.sub.3 713
TABLE-US-00002 TABLE 2 Impact of base titrant on 6A molecular
weight MALLS Run No. Base (kDa) Lab 1 3N NaOH 662 Lab 2 20%
Na.sub.2CO.sub.3 1189 Pilot 1 3N NaOH 500 Pilot 2 20%
Na.sub.2CO.sub.3 950
Effect of Bicarbonate and Mixed Base pH Titrant
[0040] In the first study (Runs L29331-122 and -139), varying
levels of initial sodium bicarbonate and base blends of sodium
hydroxide and sodium carbonate were used in conjunction with a pH
5.0 hold step after the DOC hold step. The initial bicarbonate
additions ranged from 10-50 mM and the sodium carbonate added to 3N
sodium hydroxide for the base titrant ranged from 0.2-1.8 M. One
run contained 50 mM initial bicarbonate and used NaOH as a base
titrant. The carbonate levels at the end of these fermentations
ranged from 14-111 mM. Serotype 19A molecular weights ranged from
520 to 713 kDa. Run parameters and results are shown in Table
3.
TABLE-US-00003 TABLE 3 Na.sub.2CO.sub.3 vs. mixed base as pH
titrant NaHCO.sub.3 Base MALLS PS Yield Run No. (mM)
Na.sub.2CO.sub.3 NaOH (kDa) (mg/mL) Part I E 0 20% 0 759 0.836
L29331-122 F 10 0.2M 3N 520 0.308 20 g/L HySoy G 10 0.4M 3N 648
0.538 H 10 0.9M 3N 563 0.334 Part II C 20 0.9M 3N 662 1.027
L29331-139 D 20 1.8M 3N 611 0.903 28 g/L HySoy G 50 0.9M 3N 713
0.924 H 50 0M 3N 713 1.051
[0041] A second study (L29331-159 and -185) used initial
bicarbonate additions of 15-30 mM and base blends using 0.4-1.0 M
Na.sub.2CO.sub.3. The carbonate levels at the end of fermentation
ranged from 24-62 mM. Serotype 19A molecular weights ranged from
502 to 763 kDa. Run parameters and results are shown in Table
4.
TABLE-US-00004 TABLE 4 NaHCO.sub.3 with mixed base as pH titrant
Run NaHCO.sub.3 Na.sub.2CO.sub.3/ MALLS PS Yield No. HySoy/DMS (mM)
NaOH (kDa) (mg/mL) G2 28 g/L/60 mL/L 15 1.0M/3N 657 0.853 H2 28
g/L/60 mL/L 15 0.4M/3N 605 0.755 C 20 g/L/60 mL/L 20 0.4M/3N 571
0.386 E 20 g/L/60 mL/L 20 1.0M/3N 763 0.439 F 20 g/L/60 mL/L 25
0.7M/3N 462 0.382 G 20 g/L/60 mL/L 30 0.4M/3N 502 0.355 H 20 g/L/60
mL/L 30 1.0M/3N 594 0.415
Comparison of Mixed and Pure Carbonate Titration Base Fermentation
Processes
[0042] An experiment was performed to compare the base blend
process (0.7 M Na.sub.2CO.sub.3/3 N NaOH) to the carbonate titrant
process (20% Na.sub.2CO.sub.3 solution, w/v). Results (Table 5)
confirmed that the molecular weight from the carbonate titrant
process was higher and more consistent (778, 781 kDa) than the
molecular weight from the base blend process (561-671 kDa).
Polysaccharide yield was also higher with the Na.sub.2CO.sub.3
process.
TABLE-US-00005 TABLE 5 Run L29399-1 Na.sub.2CO.sub.3 vs. mixed base
NaHCO.sub.3 Base MW PS Yield Run No. (mM) Na.sub.2CO.sub.3 NaOH
(kDa) (mg/mL) C 25 0.7M 3N 565 1.106 D 25 0.7M 3N 561 0.908 E 25
0.7M 3N 612 0.894 G 25 0.7M 3N 671 0.873 F 0 20% 0 778 1.282 H 0
20% 0 781 1.249
Pilot Scale Runs
[0043] Several serotype 19A pilot scale (100 L) runs with various
base titrants were performed. The molecular weight determination
was performed using MALLS assay following a complete purification
process and is reported from the final purified batch. Results are
shown in Table 6.
TABLE-US-00006 TABLE 6 Impact of base titrant on 19A molecular
weight at pilot scale Fermentation Purification FBC MALLS Batch
Titration Base Batch (kDa) RRP19A-0008 3N NaOH L26563-10 390
RRP19A-0009 3N NaOH L26563-11 380 IPPPN19A-005 3N NaOH/0.6M
Na.sub.2CO.sub.3 L26260-37 492 IPPPN19A-006 3N NaOH/0.6M
Na.sub.2CO.sub.3 L26260-38 480 IPPPN19A-007 3N NaOH/0.6M
Na.sub.2CO.sub.3 L26260-39 490 IPPPN19A-014 20% Na.sub.2CO.sub.3
L26260-49 580 IPPPN19A-016 20% Na.sub.2CO.sub.3 L26260-50 559
IPPPN19A-017 20% Na.sub.2CO.sub.3 L26260-51 599
Effect of Base Titrant and Overlay on 19A Molecular Weight
[0044] A set of fermentations at the 3 L scale were performed to
determine if the base titrant and atmospheric overlay affected the
molecular weight. The molecular weight determination was performed
using MALLS assay following the modified purification process.
Results are shown in Table 7.
TABLE-US-00007 TABLE 7 Impact of base titrant and overlay on 19A
molecular weight MALLS Run No. Base Overlay (kDa) Control 3N NaOH
Air 350 C 0.7M Na.sub.2CO.sub.3 Air 855 D 1.5M Na.sub.2CO.sub.3/
Air 710 1.5N NaOH E 3N NaOH 100% CO.sub.2 634 F 3N NaOH 50%
CO.sub.2 646 G 3N NaOH 20% CO.sub.2 567 H 3N NaOH 10% CO.sub.2
547
[0045] The article "a" and "an" are used herein to refer to one or
more than one (i.e., to at least one) of the grammatical object of
the article. By way of example, "an element" means one or more
element.
[0046] All publications and patent applications mentioned in the
specification are indicative of the level of those skilled in the
art to which this invention pertains. All publications and patent
applications are herein incorporated by reference to the same
extent as if each individual publication or patent application was
specifically and individually indicated to be incorporated by
reference.
[0047] Although the foregoing invention has been described in some
detail by way of illustration and example for purposes of clarity
of understanding, certain changes and modifications may be
practiced within the scope of the appended claims.
* * * * *